FMP
Oct 27, 2025
Lululemon Athletica Inc (NASDAQ:LULU) is a well-known athletic apparel company that has recently ventured into professional sports merchandising. On October 27, 2025, Jefferies set a price target of $120 for LULU, while the stock was trading at $178.17. This suggests a significant price difference of approximately -32.65% from the target. Jefferies also expressed concerns about Lululemon's partnership with the NFL, labeling it as 'questionable.'
Lululemon's partnership with the NFL and Fanatics marks its first foray into professional sports merchandising. The collaboration introduces an officially licensed apparel collection for all 32 NFL teams, featuring popular styles like Steady State, Define, Scuba, and Align. This strategic move aims to broaden Lululemon's market presence and attract a wider audience, potentially boosting its brand recognition.
Following the announcement of the NFL partnership, LULU's stock price increased by 2.7%, reaching $183.27. This rise represents the stock's highest level since a post-earnings decline in early September. Despite a 52% year-to-date deficit, the shares are now 15% above their five-year low of $159.25, recorded on September 15. Short interest in the stock has decreased by 4.6%, yet it still accounts for 8% of the total available float.
The NFL collection, set to launch on October 28, includes men's and women's apparel and accessories for all 32 teams. It will be available in Fanatics stores, a prominent sports merchandising company. The advertising campaign will feature football legend Joe Montana, further enhancing the collection's appeal. This move follows Lululemon's previous collaboration with the NHL and partnerships with athletes like Lewis Hamilton and Frances Tiafoe.
Currently, LULU's stock is priced at $182.39, reflecting a 2.37% increase. The stock has fluctuated between $182.11 and $186.91 during the trading day. Over the past year, LULU has reached a high of $423.32 and a low of $159.25. The company's market capitalization is approximately $20.7 billion, with a trading volume of 3.4 million shares on the NASDAQ exchange.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical-stage biotechnology company focused on developing gene-editing t...
State Street Corporation, trading under the symbol STT on the NYSE, is a leading financial services company that provide...